Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
$4.11
-$0.14(-2.36%)
At close: 4:00 PM EST
$4.11
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.65 - $7.44
Previous CloseN/A
Volume91.62K
Average Volume (3M)630.19K
Market Cap
$218.51M
Enterprise Value$104.05M
Total Cash (Recent Filing)$208.93M
Total Debt (Recent Filing)$38.37M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 10, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding55,600,082
10 Day Avg. Volume467,023
30 Day Avg. Volume630,191
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.09
Price to Sales (P/S)4.09
P/FCF Ratio-17.36
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$13.57Price Target Upside230.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionVoyager Therapeutics reported significant cash reserves of $229 million, providing a financial runway projected to last until 2028.
Innovative TechnologyVoyager introduced the ALPL-based NeuroShuttle, Voyager's first non-viral delivery technology, demonstrating sustained brain uptake and strong translational potential.
Strategic CollaborationVoyager announced a strategic collaboration with Transition Bio, a drug discovery company focused on biomolecular condensates, marking an expansion into small-molecule therapeutics for TDP-43–associated neurodegenerative diseases.
Bears Say
Collaborative SetbacksNVS discontinued 2 discovery stage partnered programs for undisclosed targets, indicating potential setbacks in collaborative efforts.
Price Target DecreaseA decrease in the price target to $25 from $30 was primarily driven by the removal of the anti-Aβ vectorized program.
Program DeprioritizationVoyager deprioritized the SOD1-ALS and anti-AB GTx programs to refocus efforts on new discoveries, suggesting a shift in strategic priorities.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.65 and its highest was $7.44 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $218.51M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 111 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.051.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 55,600,082 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.57 (230.17% Upside)
$13.57 (230.17% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $107.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.12%
12-Months-Change
Fundamentals
Return on Equity
-46.09%
Trailing 12-Months
Asset Growth
-32.33%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics (VYGR) is a biotechnology company focused on developing innovative gene therapies for serious neurological diseases. The company specializes in leveraging its proprietary adeno-associated viral (AAV) vector platform to deliver therapeutic genes directly to the central nervous system. Voyager's core areas of focus include conditions such as Parkinson's disease, Huntington's disease, and other neurodegenerative disorders, with a pipeline that includes both preclinical and clinical-stage programs aimed at addressing significant unmet medical needs.
VYGR Stock 12 Month Forecast
Average Price Target
$13.57
▲(230.17% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.23% Insiders
11.86% Mutual Funds
3.17% Other Institutional Investors
73.09% Public Companies and Individual Investors